RMR Wealth Builders’s Vertex Pharmaceuticals VRTX Stock Holding History

RMR Wealth Builders’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Sell	3,521 -3,589	-50%	-$1.59M	0.11%	93
2026 Q1	$3.17M	Buy	7,110 +1,321	+23%	+$616K	0.25%	57
2025 Q4	$2.62M	Buy	5,789 +466	+9%	+$201K	0.21%	65
2025 Q3	$2.08M	Buy	5,323 +223	+4%	+$93.2K	0.17%	73
2025 Q2	$2.27M	Buy	5,100 +265	+5%	+$122K	0.21%	62
2025 Q1	$2.34M	Buy	4,835 +596	+14%	+$278K	0.25%	54
2024 Q4	$1.71M	Buy	4,239 +351	+9%	+$163K	0.18%	70
2024 Q3	$1.81M	Sell	3,888 -344	-8%	-$165K	0.19%	66
2024 Q2	$1.98M	Buy	4,232 +484	+13%	+$210K	0.23%	55
2024 Q1	$1.57M	Buy	3,748 +783	+26%	+$331K	0.19%	64
2023 Q4	$1.21M	Buy	2,965 +393	+15%	+$145K	0.17%	74
2023 Q3	$894K	Buy	+2,572	New	+$900K	0.14%	77

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

RMR Wealth Builders's VRTX Position: Q2 2026 in Review

RMR Wealth Builders reduced its Vertex Pharmaceuticals (VRTX) stake by 50% in Q2 2026, selling an estimated $1.59M and leaving 3,521 shares worth $1.75M. The position accounts for 0.11% of the portfolio, ranked #93.

RMR Wealth Builders first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.17M in Q1 2026. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

RMR Wealth Builders held 3,521 shares of Vertex Pharmaceuticals worth $1.75M as of Q2 2026.
RMR Wealth Builders sold 3,589 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.59M.
Vertex Pharmaceuticals made up 0.11% of RMR Wealth Builders's portfolio in Q2 2026, its #93 holding.
RMR Wealth Builders first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
RMR Wealth Builders's Vertex Pharmaceuticals position peaked at $3.17M in Q1 2026.
1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on RMR Wealth Builders's 13F filing for Q2 2026, filed 24 Jul 2026.